This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Di Munno, O Articles by Bombardieri, S Search for Related Content PubMed PubMed Citation Articles by Di Munno, O Articles by Bombardieri, S Social Bookmarking                         What's this?

Risk factors for osteoporosis in female patients with systemic lupus erythematosus

Rheumatology Unit, Department of Internal Medicine, University of Pisa, Pisa, Italy, o.dimunno{at}int.med.unipi.it

M Mazzantini

Rheumatology Unit, Department of Internal Medicine, University of Pisa, Pisa, Italy

A Delle Sedie

Rheumatology Unit, Department of Internal Medicine, University of Pisa, Pisa, Italy

M Mosca

Rheumatology Unit, Department of Internal Medicine, University of Pisa, Pisa, Italy

S Bombardieri

Rheumatology Unit, Department of Internal Medicine, University of Pisa, Pisa, Italy

In the last years it has been recognized that patients with systemic lupus erythematosus (SLE) are at high risk of osteoporosis (OP) and fractures, both occurring through disease-specific (chronic arthritis, reduced physical activity, induction of cytokines promoting bone resorption, renal impairment, endocrine factors) and nondisease-specific mechanisms (sunshine avoidance with consequent vitamin D deficiency, glucocorticoids, immunosuppressants and chronic anticoagulants). Regarding anticoagulants, subcutaneous heparin is crucial against the risk of recurrent thromboembolism or pregnancy loss, specifically in patients with SLE and anti-phospholipid syndrome (APS). Thus heparin-induced OP represents one of the hazards of this treatment, first because heparin must be used long-term and secondly because pregnancy and lactation themselves may predispose to OP and fractures. Current data suggest the use of prophylaxis with calcium and vitamin D in all patients treated with heparin during pregnancy. Nevertheless glucocorticoid-induced OP (GIOP) is considered the most serious risk factor for OP and fractures in SLE patients. All guidelines recommend general measures and supplementation with calcium and vitamin D in all patients. However when considering premenopausal patients, there is no generally recommended treatment. Bisphosphonates, which are considered the first choice therapy for the prevention and treatment of GIOP, should be used ‘cautiously’ in these patients. Therefore the potential risks and lack of efficacy data on fracture risk reduction in premenopausal patients must be weighed against their proven efficacy in postmenopausal patients.

Key Words: fractures • osteoporosis • prevention • risk factors • systemic lupus erythematosus

Lupus, Vol. 13, No. 9, 724-730 (2004)
DOI: 10.1191/0961203303lu1097oa


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				F. Falcini and F. Nacci Review: Systemic lupus erythematosus in the young: the importance of a transition clinic Lupus, August 1, 2007; 16(8): 613 - 617. [Abstract] [PDF]

				L. Shinchuk and M. F. Holick Vitamin D and Rehabilitation: Improving Functional Outcomes Nutr Clin Pract, June 1, 2007; 22(3): 297 - 304. [Abstract] [Full Text] [PDF]

				M. F. Holick High Prevalence of Vitamin D Inadequacy and Implications for Health Mayo Clin. Proc., March 1, 2006; 81(3): 353 - 373. [Abstract] [Full Text] [PDF]